ClinicalTrials.gg
CompletedNCT03926819Updated May 23, 2025Results posted

A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

A Phase 1 interventional study of HBI-002 in Anemia, Sickle Cell, sponsored by Hillhurst Biopharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by Hillhurst Biopharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
366th of 559
20 · median 31
Started
2022
with 40 others
Phase 1
98 of 733
13 open now
Registered
447th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 366th largest by enrollment of the 559 interventional ones that give a count, is one of 41 that started in 2022, is one of 98 in phase 1, and was the 447th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This is a single center, open label Phase 1 clinical trial in normal adult subjects to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with single ascending doses (SAD), followed by multiple dose with doses daily for 7 days.

03

Conditions studied

  • Anemia, Sickle Cell

Keywords

  • Anemia, Sickle Cell
  • Anemia, Hemolytic, Congenital
  • Anemia, Hemolytic
  • Anemia
  • Hematologic Diseases
  • Hemoglobinopathies
  • Genetic Diseases, Inborn
  • Carbon Monoxide
  • CO
  • Heme Oxygenase
  • HO-1
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Healthy male or female 18-55 years of age inclusive.
  3. Negative , aHCV, aHIV, and SARS-CoV-2 test.
  4. Non-smoker or vaper (no use of tobacco or marijuana products within 3 months of screening).
  5. Body weight between 60 kg and 110 kg (inclusive) and with less than 30 kg/m2.
  6. Subjects must be healthy as defined by:

    1. absence of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic disease, as determined by the Investigator.
    2. liver function: (ALT) and aspartate transaminase (AST) ≤2 times the
    3. total ≤1.5 times the upper limit of the normal range
    4. renal function: within normal range as assessed by Cockcroft and Gault calculation
    5. carboxyhemoglobin level by venous blood gas ≤ 3.5% (any time prior to the first dose)
    6. venous lactate level \<2.0 mmol/L at baseline.
    7. the absence of current clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure and pulse rate measurement, 12-lead , and clinical laboratory tests (hematology and clinical chemistries), as determined by the Investigator.
  7. Negative pregnancy tests for females.
  8. Subjects must be willing to use a highly effective method of for the duration of the study and for 30 days thereafter.

    1. Male subjects, without a vasectomy, must use a condom and be instructed that their female partner should use another form of contraception such as an IUD, diaphragm with spermicide, oral contraceptive, injectable progesterone, subdermal implant or a tubal ligation if the female partner could become pregnant
    2. Female subjects of (not surgically sterilized and less than one year ) should use a form of contraception such as an IUD, diaphragm with spermicide, oral contraceptive, injectable progesterone, subdermal implant or a tubal ligation, and be instructed that their male partners should use a condom, if not vasectomized.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will be ineligible for participation in the study:

  1. Subjects with concurrent illness/disease as defined by:

    1. hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic disease, as determined by the Investigator.
    2. current clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure and pulse rate measurement, 12-lead , and clinical laboratory tests (hematology, clinical chemistries and urinalysis), as determined by the Investigator.
    3. clinically significant illness and/or surgery within 4 weeks prior to dosing.
  2. Anemia of any cause.
  3. Homozygous or heterozygous hemoglobinopathy.
  4. Blood transfusion within six weeks prior to the first administration of study drug.
  5. Carboxyhemoglobin ≥ 3.5% (any time prior to the first dose)
  6. Oxygen saturation by transcutaneous measurement consistently ≤ 95% (any time prior to the first dose)
  7. Exposure to any within 28 days prior to study drug administration.
  8. History of febrile or infective illness within 14 days prior to dosing.
  9. Positive pregnancy test or breast feeding for females.
  10. Weight loss or gain of more than 5 kg within 3 months prior to dosing.
  11. History of alcohol abuse or dependence or regular use of alcohol within six months prior to dosing (defined as more than 14 units of alcohol per week; 1 Unit= 150 mL wine, 360 mL beer or 45 mL of 40% alcohol)
  12. Positive result on alcohol screen
  13. History of pulmonary infiltrate or pneumonia within 6 months prior to dosing or pulmonary/bronchial infection within 2 weeks prior to dosing.
  14. History of cancer, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin more than 1 year prior.
  15. History of cardiac disease
  16. History of drug abuse or dependence.
  17. Positive results on drug screen (oxycodone, benzodiazepines, THC, cocaine, opiates, and methamphetamine).
  18. Use of prescription drugs within 7 days or 5 half-lives (whichever is longer) prior to dosing. Herbal and vitamin supplements must be discontinued 14 days prior to dosing.
  19. Unwilling or unable to comply with the requirements of the protocol.
  20. Treatment with an drug within the longer of 30 days or five half-lives.
  21. Systolic blood pressure lower than 90 or above 140 mm Hg, diastolic blood pressure lower than 50 or above 90 mm Hg, heart rate less than 45 or above 100 bpm, or arrhythmia at screening and/or baseline. ECG abnormalities or other vital sign abnormalities that are clinically significant at screening and/or baseline, as determined by the Investigator.
  22. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into the study.
  23. History of allergic reactions to any of the drug product
  24. History of epilepsy or seizure
  25. History of suicide attempts or ideation (by medical history)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Single Ascending Dose

    Drug: HBI-002

  • Active comparator
    Multiple Ascending Dose

    Drug: HBI-002

Interventions

  • Oral liquid carbon monoxide drug product.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 of dosing, up to 30 days post-dose for SAD cohorts. Day 1 of dosing to 30 days post last dose, up to 37 days for MAD cohort

  2. Cmax

    Maximum COHb Concentration (Cmax), measured by blood gas machine with co-oximetry

    Time frame: Blood samples will be drawn on Day 1 immediately before and after dosing at 30, 60, 90, 120 minutes and at 3, 4, 5, 6, 24, 48, and 72 hours

07

Results

Posted May 23, 2025

Participant flow

Participant flow — Overall Study
MilestoneSingle Ascending Dose - 0.7 mg/kgSingle Ascending Dose - 1.3 mg/kgSingle Ascending Dose - 2.7 mg/kgSingle Ascending Dose - 3.7 mg/kgMultiple Dose - 4.4, 3.6, 2.7 mg/kg
Started44444
Completed44443
Not completed00001

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Time frame:
Day 1 of dosing, up to 30 days post-dose for SAD cohorts. Day 1 of dosing to 30 days post last dose, up to 37 days for MAD cohort
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsSingle Ascending Dose - 0.9 mg/kgSingle Ascending Dose - 1.8 mg/kgSingle Ascending Dose - 3.6 mg/kgSingle Ascending Dose - 5.0 mg/kgMultiple Dose
Serious Adverse Events (SAEs)00000
Severe TEAEs00000
Moderate TEAEs00000
Mild TEAEs21033
PrimaryCmax

Maximum COHb Concentration (Cmax), measured by blood gas machine with co-oximetry

Time frame:
Blood samples will be drawn on Day 1 immediately before and after dosing at 30, 60, 90, 120 minutes and at 3, 4, 5, 6, 24, 48, and 72 hours
Reported as:
Mean · percentage COHb saturation
Cmax
percentage COHb saturationSingle Ascending Dose - 0.9 mg/kgSingle Ascending Dose - 1.8 mg/kgSingle Ascending Dose - 3.6 mg/kgSingle Ascending Dose - 5.0 mg/kgMultiple Dose
Cmax3.4 ± 0.13.8 ± 0.55.7 ± 1.76.9 ± 1.68.7 ± 1.3

Adverse events

Collected over Day 1 of dosing, up to 30 days post-dose for SAD cohorts. Day 1 of dosing to 30 days post last dose, up to 37 days for MAD cohort. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SAD - 0.9 mg/kg0/4 (0%)0/4 (0%)2/4 (50%)
SAD - 1.8 mg/kg0/4 (0%)0/4 (0%)1/4 (25%)
SAD - 3.6 mg/kg0/4 (0%)0/4 (0%)0/4 (0%)
SAD - 5.0 mg/kg0/4 (0%)0/4 (0%)3/4 (75%)
Multiple Dose0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent other events
Most frequent other events
EventSAD - 0.9 mg/kgSAD - 1.8 mg/kgSAD - 3.6 mg/kgSAD - 5.0 mg/kgMultiple Dose
Nervous System DisordersNervous system disorders1/40/40/43/40/4
Gastrointestinal disordersGastrointestinal disorders0/41/40/41/42/4
General disorders and administration site conditionsGeneral disorders0/41/40/41/40/4
InvestigationsInvestigations1/40/40/41/41/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)SAD - 0.9 mg/kgSAD - 1.8 mg/kgSAD - 3.6 mg/kgSAD - 5.0 mg/kgMultiple DoseTotal
Mean38 ± 839 ± 1239 ± 938 ± 740 ± 839 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)SAD - 0.9 mg/kgSAD - 1.8 mg/kgSAD - 3.6 mg/kgSAD - 5.0 mg/kgMultiple DoseTotal
Female100124
Male3443216
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SAD - 0.9 mg/kgSAD - 1.8 mg/kgSAD - 3.6 mg/kgSAD - 5.0 mg/kgMultiple DoseTotal
American Indian or Alaska Native000000
Asian110103
Native Hawaiian or Other Pacific Islander000000
Black or African American131128
White202228
More than one race001001
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(Participants)SAD - 0.9 mg/kgSAD - 1.8 mg/kgSAD - 3.6 mg/kgSAD - 5.0 mg/kgMultiple DoseTotal
United States4444420
08

Study locations

1 site
  • Contact Company
    San Diego, California 92121, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Apr 2023, 9 months.

Results were first posted in May 2025, 2 years after primary completion.

Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 9 months is below that.

Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2019
First posted
Apr 25, 2019
StartActual
Jul 25, 2022
Primary completionActual
Apr 26, 2023
CompletionActual
Apr 26, 2023
Results first posted
May 23, 2025
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03926819
Lead sponsor
Hillhurst Biopharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Apr 25, 2019
Start date
Jul 25, 2022
Primary completion
Apr 26, 2023
Completion
Apr 26, 2023
Results posted
May 23, 2025
Last update
May 23, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBI-002

Start the discussion